Management of Ewing sarcoma family of tumors: Current scenario and unmet need

Table 4 Data on Irinotecan-temozolamide salvage regimen in recurrent/refractory Ewing sarcoma family tumors

Ref.	n	Irinotecan schedule	ORR (n)	Toxicity (grade 3 and 4)
Kurucu et al[65]	20	20 mg/m2 (D1-5 and D8-D12)	55% (11)	Diarrhea - 9.2%
				Neutropenia - 11.3%
McNall-Knapp et al[64]	25	15 mg/m2vs 20 mg/m2 (D1-5 and D8-D12)1	20% (5)	Diarrhea - 5%
Raciborska et al[63]	22	50 mg/m2 (D1-D5)1	50% (12)	Diarrhea - 15%
				Hematological - 10%
Wagner et al[62]	16	10-20 mg/m2 (D1-5 and D8-D12) - 3 weekly vs 4 weekly	25% (4)	Diarrhea - 11%
Casey et al[61]	20	20 mg/m2 (D1-5 and D8-D12)	63%	Diarrhea - 4.5%
				Hematological - 22%

¹With vincristine. ESFT: Ewing sarcoma family of tumors; n: Number; ORR: Overall response rate.